Thorac Cardiovasc Surg 2017; 65(S 03): S167-S173
DOI: 10.1055/s-0037-1601375
Tribute
Georg Thieme Verlag KG Stuttgart · New York

Treatment of Coronary Artery Disease: Randomized Trials on Myocardial Revascularization and Complete Arterial Bypass Grafting

Ardawan J. Rastan
1   Department of Cardiac and Vascular Surgery, Herz-Kreislauf-Zentrum Rotenburg, Rotenburg, Germany
› Author Affiliations
Further Information

Publication History

02 March 2017

02 March 2017

Publication Date:
07 April 2017 (online)

Abstract

Friedrich Wilhelm Mohr from the very beginning of his career as a cardiac surgeon was involved in the refinements of coronary artery bypass grafting (CABG). At the Leipzig Heart Center, his spirit of early adapting to new technologies inspired the entire team and led to a matchless scientific atmosphere to find solutions to improve almost all fields of cardiac surgery, including CABG. In combination with a tremendous number of patients with indications for isolated coronary artery bypass Prof. Mohr as the surgical principle investigator and the Leipzig Heart Center were able to include patients in the Synergy between PCI [percutaneous coronary intervention] with Taxus and Cardiac Surgery (SYNTAX) trial, the first randomized trials comparing CABG and PCIs using the drug-eluting stents. Final SYNTAX results after 5 years gave direction and scientific evidence for contemporary European revascularization guidelines. These guidelines recommend PCI as an alternative first-line treatment option in patients with coronary three-vessel disease and left main stenosis having low coronary complexity based on the angiographic SYNTAX score. However, the study demonstrated the significant superiority of CABG over PCI in all other patients, especially in these with complex three-vessel disease. The specific characteristic of the SYNTAX study is that the distinguished results were confirmed by several post-SYNTAX comparative randomized trials on coronary revascularization including left main disease and clinical registries even when contemporary drug-eluting stent designs were used. When performing CABG the question of the best second graft remains unclear. While several mono-institutional reports and large meta-analyses demonstrated clear superiority in terms of long-term survival when using bilateral mammary versus single mammary revascularization, this benefit could not be confirmed in randomized trials after 5 years.

 
  • References

  • 1 Mohr FW, Matloff J, Grundfest W , et al. Thermal coronary angiography: a method for assessing graft patency and coronary anatomy in coronary bypass surgery. Ann Thorac Surg 1989; 47 (3) 441-449
  • 2 Falk V, Jacobs S, Gummert JF, Walther T, Mohr FW. Computer-enhanced endoscopic coronary artery bypass grafting: the da Vinci experience. Semin Thorac Cardiovasc Surg 2003; 15 (2) 104-111
  • 3 Serruys PW, Morice MC, Kappetein AP , et al; SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009; 360 (10) 961-972
  • 4 Mohr FW. To beat or not to beat? From one size fits it all to an individual coronary revascularization strategy. Eur Heart J 2010; 31 (20) 2441-2443
  • 5 Mohr FW, Morice MC, Kappetein AP , et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013; 381 (9867): 629-638
  • 6 Head SJ, Davierwala PM, Serruys PW , et al. Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial. Eur Heart J 2014; 35 (40) 2821-2830
  • 7 Mohr FW, Davierwala PM. Coronary artery bypass surgery continues to remain the treatment of choice for multivessel coronary artery disease even in the era of new-generation drug-eluting stents. Evid Based Med 2015; 20 (4) 142
  • 8 Kappetein AP, Head SJ, Morice MC , et al; SYNTAX Investigators. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J Cardiothorac Surg 2013; 43 (5) 1006-1013
  • 9 Kolh P, Windecker S, Alfonso F , et al; European Society of Cardiology Committee for Practice Guidelines; EACTS Clinical Guidelines Committee; Task Force on Myocardial Revascularization of the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery; European Association of Percutaneous Cardiovascular Interventions. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg 2014; 46 (4) 517-592
  • 10 Milojevic M, Head SJ, Andrinopoulou ER , et al. Hierarchical testing of composite endpoints: applying the win ratio to percutaneous coronary intervention versus coronary artery bypass grafting in the SYNTAX trial. EuroIntervention 2017; (e-pub ahead of print) DOI: 10.4244/EIJ-D-16-00745.
  • 11 Weintraub WS, Grau-Sepulveda MV, Weiss JM , et al. Comparative effectiveness of revascularization strategies. N Engl J Med 2012; 366 (16) 1467-1476
  • 12 Sipahi I, Akay MH, Dagdelen S, Blitz A, Alhan C. Coronary artery bypass grafting vs percutaneous coronary intervention and long-term mortality and morbidity in multivessel disease: meta-analysis of randomized clinical trials of the arterial grafting and stenting era. JAMA Intern Med 2014; 174 (2) 223-230
  • 13 Desch S, Boudriot E, Rastan A , et al. Bypass surgery versus percutaneous coronary intervention for the treatment of unprotected left main disease. A meta-analysis of randomized controlled trials. Herz 2013; 38 (1) 48-56
  • 14 Farkouh ME, Domanski M, Sleeper LA , et al; FREEDOM Trial Investigators. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012; 367 (25) 2375-2384
  • 15 Bangalore S, Guo Y, Samadashvili Z, Blecker S, Xu J, Hannan EL. Everolimus-eluting stents or bypass surgery for multivessel coronary disease. N Engl J Med 2015; 372 (13) 1213-1222
  • 16 Park SJ, Ahn JM, Kim YH , et al; BEST Trial Investigators. Trial of everolimus-eluting stents or bypass surgery for coronary disease. N Engl J Med 2015; 372 (13) 1204-1212
  • 17 Mäkikallio T, Holm NR, Lindsay M , et al; NOBLE study investigators. Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial. Lancet 2016; 388 (10061): 2743-2752
  • 18 Stone GW, Sabik JF, Serruys PW , et al; EXCEL Trial Investigators. Everolimus-eluting stents or bypass surgery for left main coronary artery disease. N Engl J Med 2016; 375 (23) 2223-2235
  • 19 Velazquez EJ, Lee KL, Jones RH , et al; STICHES Investigators. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med 2016; 374 (16) 1511-1520
  • 20 Lytle BW, Blackstone EH, Sabik JF, Houghtaling P, Loop FD, Cosgrove DM. The effect of bilateral internal thoracic artery grafting on survival during 20 postoperative years. Ann Thorac Surg 2004; 78 (6) 2005-2012 , discussion 2012–2014
  • 21 Takagi H, Goto SN, Watanabe T, Mizuno Y, Kawai N, Umemoto T. A meta-analysis of adjusted hazard ratios from 20 observational studies of bilateral versus single internal thoracic artery coronary artery bypass grafting. J Thorac Cardiovasc Surg 2014; 148 (4) 1282-1290
  • 22 Parasca CA, Head SJ, Mohr FW , et al; SYNTAX Investigators. The impact of a second arterial graft on 5-year outcomes after coronary artery bypass grafting in the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery Trial and Registry. J Thorac Cardiovasc Surg 2015; 150 (3) 597-606.e2
  • 23 Taggart DP, Altman DG, Gray AM , et al; ART Investigators. Randomized trial to compare bilateral vs. single internal mammary coronary artery bypass grafting: 1-year results of the Arterial Revascularisation Trial (ART). Eur Heart J 2010; 31 (20) 2470-2481
  • 24 Taggart DP, Altman DG, Gray AM , et al; ART Investigators. Randomized trial of bilateral versus single internal-thoracic-artery grafts. N Engl J Med 2016; 375 (26) 2540-2549
  • 25 Serruys PW, Chevalier B, Sotomi Y , et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet 2016; 388 (10059): 2479-2491
  • 26 Bønaa KH, Mannsverk J, Wiseth R , et al; NORSTENT Investigators. Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease. N Engl J Med 2016; 375 (13) 1242-1252